gabexate has been researched along with Renal Insufficiency, Chronic in 2 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ueda, M | 2 |
Uchimura, K | 2 |
Narita, Y | 2 |
Miyasato, Y | 2 |
Mizumoto, T | 2 |
Morinaga, J | 2 |
Hayata, M | 2 |
Kakizoe, Y | 2 |
Adachi, M | 2 |
Miyoshi, T | 2 |
Shiraishi, N | 1 |
Kadowaki, D | 2 |
Sakai, Y | 2 |
Mukoyama, M | 2 |
Kitamura, K | 2 |
Nakagawa, T | 1 |
Hirata, S | 1 |
2 other studies available for gabexate and Renal Insufficiency, Chronic
Article | Year |
---|---|
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Creatinine; Disease Progression; Est | 2015 |
Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazol | 2016 |